tbuckley/cabot-search huggingface dataset:
Azithromycin doesn't prevent recurrent acute coronary syndromes
Journal: BMJ (2003)

Poor education was associated with mortality in 1990s RussiaDuring the economic breakdown in Russia in the 1990s the greatest increases in mortality were among men with little education.Plavinski and colleagues (p 1240) used data from two prospective cohorts generated from voting lists in Leningrad (now Saint Petersburg) during the mid-1970s and 1980s.They found that men with university degrees were unaffected by the increased mortality, whereas men with less than high school education were most affected.Low education is a risk for mortality that cannot be fully explained by other risk factors, particularly during times of economic trouble.
THE CHARACTERS OF A THIRD TRANSPLANTABLE CHICKEN TUMOR DUE TO A FILTERABLE CAUSE. A SARCOMA OF INTRACANALICULAR PATTERN
Authors: Peyton Rous, Linda B. Lange
Journal: The Journal of Experimental Medicine (1913)

In Volume XVIII, Number 6, December, 1913, page 662, line 23 and following should read: Finally, artificial attenuation of the agent causing Chicken Tumor I, by heating, or glycerination, or storage after drying, has never so altered it that it will produce tumors resembling Chicken Tumor XVIII. The agents causing the two growths may nevertheless have some relationship to each other.
Hypothyroidism
Authors: Sharon Parmet
Journal: JAMA (2003)

HypothyroidismT he thyroid gland is a small butterfly-shaped structure located in the front of the neck.Hypothyroidism (low thyroid function) occurs when the thyroid gland does not produce enough of a substance called thyroid hormone, which helps to regulate the body' s metabolism.Hypothyroidism develops in about 5% of the population in the United States and is especially common in women older than 60 years.The December 10, 2003, issue of JAMA includes an article about treating hypothyroidism.
TMOD-38. GMYC: A NOVEL INDUCIBLE TRANSGENIC MODEL OF GROUP 3 MEDULLOBLASTOMA
Authors: Gabriela Rosén, Holger Weishaupt, Oliver Mainwaring, Fredrik Swartling
Journal: Neuro-Oncology (2018)

Group 3 medulloblastoma (MB) carry the worst prognosis of all MB. The transcription factors MYC and MYCN have been suggested drivers for a subset of these tumors, with MYC amplifications (17–20%) representing the most common genetic alteration in Group 3 tumors, while MYCN amplifications (4–6%) are less frequent. To improve current treatment options for these patients, it is of crucial importance to decipher differential features of MYCN- and MYC-driven MB and to establish accurate animal models for these patients. By driving MYC from the hindbrain-specific Glutamate transporter 1 (Glt1) promoter using a Tet-OFF system we established a novel murine model of MYC-driven MB (GMYC), which accurately recapitulates aggressive Group 3 MB. GMYC tumors develop without any p53 mutations and with ~70% penetrance. Tumor-prone GMYC mice can further be cured by MYC-depletion through dox treatment. Comparison of transcriptional profiles between GMYC and our MYCN-driven GTML tumors revealed that both models accurately represent Group 3 MB, while showing differential expression of key features of MYC- or MYCN-driven tumors. CDKN2A was identified as one of the top upregulated genes in our GTML model as compared to our GMYC model. CDKN2A encodes two tumor suppressors, p16INK4A and p14ARF, which are key regulators of cell cycle progression and activation of p53. Similar enhancement of CDKN2A was observed in MYCN-amplified as compared to MYC-amplified Group 3/4 patients. Tumor formation following partial or complete knockout of CDKN2A significantly increased tumor penetrance in GTML as compared to GMYC animals. Similarly, CDKN2A levels significantly correlate with poor prognosis in MYCN amplified MB patients while as compared to MYC amplified patients were CDKN2A levels are low. This suggests that MYC is regulating and suppressing CDKN2A during MB formation and further advocates that pharmacological restoration of CDKN2A would be a potential future therapy for this group of high-risk MB patients.
Consultants' views of general practitioners
Authors: W. Belton
Journal: BMJ (1967)

SIR,-On examining the recently published figures (Supplement, 7 October, p. 3) for medical staffing in the National Health Service at registrar and S.H.O.levels one should under " traumatic and orthopaedic surgery" really read " casualty."If the departments which are major employers of these grades are compared the following figures are obtained.The total numbers are given in brackets, followed by the percentage of graduates born
Uncompensated and discounted Medicaid care provided by physician group practices in Wisconsin
Authors: N. C. Dunham
Journal: JAMA (1991)

A survey of a sample of physician group practices in Wisconsin was undertaken to determine the amounts of charity care, bad debt, and discounted Medicaid care that were provided in 1988. Overall, the physician group practices in the sample reported dollar amounts of uncompensated care and discounted Medicaid care that averaged approximately 7.6% of their total billings for the year (1.6% of charity care, 3.0% of bad debt, and 3.0% of discounted Medicaid care). From the dollar totals reported, it was calculated that the individual physicians represented by this sample of group practices were responsible for, on average, $4300 of charity care, $9100 of bad debt, and $7500 of Medicaid discounted services, for a yearly per-physician total of $20 900 of uncompensated care and discounted care provided to uninsured and indigent patients. The results indicate that a majority of the group practices provided more charity care in 1988 than they had 5 years earlier and suggest that the burden of providing uncompensated care tends to fall disproportionately on those group practices that are also providing relatively high levels of service to Medicaid recipients. (<i>JAMA</i>. 1991;265:2982-2986)
Response
Authors: K. C. CHU, C. R. SMART
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article Response Get access KENNETH C. CHU, KENNETH C. CHU Division of Cancer Prevention and Control National Cancer InstituteExecutive Plaza North, Rm. 305 National Institutes of Health Bethesda, MD 20892 Search for other works by this author on: Oxford Academic PubMed Google Scholar CHARLES R. SMART CHARLES R. SMART Division of Cancer Prevention and Control National Cancer InstituteExecutive Plaza North, Rm. 305 National Institutes of Health Bethesda, MD 20892 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 3, 1 February 1989, Page 235, https://doi.org/10.1093/jnci/81.3.235 Published: 01 February 1989
What Is Hazardous? What Is Safe?
Authors: John W. Healy
Journal: Environmental Health Perspectives (1978)

The definition of an acceptable risk involves many facets most of which are outside the control of the decision maker, but they must be recognized if a proper definition is to be made. Six of the principal factors are stated and discussed. (1) nothing is absolutely safe; (2) each individual or group of individuals has his own standards by which he judges risk; (3) perceptions of risk vary with the conditions at any one time in history; (4) there must be a compensatory benefit for taking any risk; (5) societal perception of a risk may be different from the actual risk; and (6) safety is only one of the many factors that must be considered in the design of a product or service.
Constitutively Activated STAT3 Promotes Cell Proliferation and Survival in the Activated B Cell Subtype of Diffuse Large B Cell Lymphomas.
Authors: Bihui Hilda Ye, Beibei Belinda Ding, Jian Jessica Yu, Raymond Y.-L. Yu, Lourdes M. Mendez, Rita Shaknovich, Yonghui Zhang, Giorgio Cattoretti
Journal: Blood (2007)
Visualization of the uptake and processing of oxidized low-density lipoproteins in human and rat liver
Authors: S Esbach
Journal: Hepatology (1993)

The interaction of oxidized human low-density lipoproteins with human and rat liver was analyzed by light and electron microscopy. At the light microscopic level oxidized low-density lipoprotein was visualized by the fluorescent dye 1,1′ dioctadecyl 3,3,3′,3′ tetramethyl indocarbocyanine perchlorate, whereas at the electron microscopic level, an indirect immunolabeling procedure was used that detected the apoprotein B of the oxidized low-density lipoprotein. In rats, oxidized low-density lipoprotein was administered intravenously, and uptake by human liver was studied by perfusion of tissue blocks. Both in human and in rat liver, fluorescently labeled oxidized low-density lipoprotein was mainly found to become concentrated in Kupffer cells and, to a lesser extent, in endothelial cells. In both species the cell association of fluorescently labeled oxidized low-density lipoprotein could be inhibited by preadministration of polyinosinic acid, indicating a scavenger receptor-mediated process. At the electron microscopic level, oxidized low-density lipoprotein was found to bind mainly to areas of the plasma membrane of the Kupffer cells without clathrin coating, although binding to coated regions was also noticed. Internalization of the ligand occurred through coated vesicle formation and through membrane folding of interacting lamellipodia and wormlike structures. No indication for phagocytosis of aggregated oxidized low-density lipoprotein particles was noticed. After internalization, the immunoreactive oxidized low-density lipoprotein was detected in relatively electron-lucent endosomes and, subsequently, in lysosomes. Endothelial cells internalized oxidized lowdensity lipoprotein solely through coated pits, after which the particles were transferred through endosomes into lysosomes. The endosomes often contained tubular extensions, which were devoid of immunolabel. In human Kupffer and endothelial liver cells, essentially the same organelles were demonstrated to be involved in the internalization and processing of oxidized low-density lipoprotein as in the rat. Our morphological results confirm earlier biochemical data on the relative involvement of the various liver cell types in the uptake of oxidized low-density lipoprotein in rats, and the relevance of these data for the human situation is indicated. The uptake process, coupled to oxidized low-density lipoprotein recognition by Kupffer cells, as presently analyzed, indicates that both rat and human Kupffer cells are equipped with a similar removal system to protect the body against the occurrence of the atherogenic oxidized low-density lipoprotein particles in the blood. (HEPATOLOGY 1993;18:537–545.)
Retraction
Journal: Annals of the Rheumatic Diseases (2014)

91) manipulated several assays used in the studies presented.By adding anti-IgE antibodies into the tubes containing citrullinated fibrinogen, it seemed that the activation of basophils resulted from exposure to citrullinated fibrinogen.Likewise, controls and samples were manipulated through transfer of cells from positive controls to other tubes that now also appeared to contain a positive reaction.This was done in the absence of all other investigators who did not have knowledge of these irregularities.After discovery of these events, several experiments were performed with the goal to reproduce the data indicating the presence of IgE ACPA.The validity of these data could not be confirmed.Therefore, part of the data summarised in the review published in Annals of the Rheumatic Diseases are incorrect.For these reasons, the authors wish to retract the publication that appeared in Annals of the Rheumatic Diseases from the scientific record.The Leiden University Medical Centre has completed an investigation by an independent investigation committee into the violation of scientific integrity and irregularities and has concluded that sole responsibility for
THYROTOXICOSIS AND LYMPHOID HYPERPLASIA
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In Vitro Effect of Testosterone and 17 β-Estradiol on LLeucine-C14 Incorporation into Human Breast Cancer Tissue
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Antibiotic batch certification and bioequivalence
Authors: K. A. DeSante
Journal: JAMA (1975)

All antibiotics marketed in the United States must undergo batch certification by the Food and Drug Administration. It is often assumed that the different brands of a particular antibiotic that pass in vitro batch certification tests have equal in vivo bioavailability. The fallacy of this assumption is clearly supported for commercially available lots of tetracycline hydrochloride that had passed batch certification tests yet had different serial serum concentrations. (<i>JAMA</i>232:1349-1351, 1975)
Venous thrombosis results from some phenol injections
Authors: C. Macek
Journal: JAMA (1983)

Injections of dilute phenol solutions to produce either chemical neurolysis or motor point blocks are considered safe and effective methods to control muscle spasticity in some handicapped patients. But most physicians don't realize that deep venous thrombosis is a possible complication of the procedures, say two physicians. Spasticity is common in patients with spinal cord and brain injuries, multiple sclerosis, cerebral palsy, and after cerebrovascular accidents. Often spasticity is controlled by medications such as diazepam, baclofen, dantrolene sodium, or opiates as well as through range-of-motion exercises, external cooling of the muscles, or even biofeedback (<i>JAMA</i>MEDICAL NEWS, 1983:249;1533-1536). If these therapies are not successful, then phenol injections can be used as an intermediate step prior to ablative surgical procedures involving the peripheral nerves, spinal cord roots or the cord itself, says Marc S. Kallins, MD, director of physical medicine at the L. W. Blake Memorial Hospital in Bradenton and Happiness
Get Smart About Antibiotics Week — November 16–22, 2015
Authors: Ahmed Jamal, David Homa, Erin O'connor, Stephen Babb, Ralph Caraballo, Tushar Singh, ; Hu, Brian King, Thomas Frieden, Harold Jaffe, Joanne Cono, Chesley Richards, Michael Iademarco, Sonja Rasmussen, Charlotte Kent, Jacqueline Gindler, Teresa Rutledge, Douglas Weatherwax, Soumya Dunworth, Teresa Hood, Martha Boyd, Maureen Leahy, Julia Martinroe, Stephen Spriggs, Moua Yang, Quang Doan, Phyllis King, Teresa Moreland, Terraye Starr, Timothy Jones, Matthew Boulton, Virginia Caine, Katherine Daniel, Jonathan Fielding, David Fleming, William Halperin, King Holmes, Robin Ikeda, Rima Khabbaz, Phyllis Meadows, Jewel Mullen, Jeff Niederdeppe, Patricia Quinlisk, Patrick Remington, Carlos Roig, William Roper, William Schaffner
Journal: MMWR Morbidity and Mortality Weekly Report (2015)

Sponsored by the American Cancer Society, the Great American Smokeout is an annual event that encourages smokers to make a plan to quit, or to plan in advance and quit smoking on that day, in an effort to stop smoking permanently (1).The 40th annual Great American Smokeout will be held on November 19, 2015.In the more than 50 years since the first Surgeon General's report on smoking and health, cigarette smoking among U.S. adults has been reduced by half.However, since 1964, an estimated 20 million persons have died because of smoking, which is the leading preventable cause of disease, disability, and death in the United States (2).About two out of three adult smokers want to quit smoking cigarettes, and more than half made a quit attempt in the preceding year (2).However, in 2014, an estimated 16.8% (approximately 40 million) of U.S. adults still smoke (3).Getting effective help through counseling and medications can increase the chances of quitting by as much as three-fold (4).
Transplantation
Authors: Paul S. Russell, Henry J. Winn
Journal: New England Journal of Medicine (1970)

FROM the clinician's practical point of view the wider application of transplantation as a remedy for disease is being restrained by a number of factors. The available supply of organs in an acceptable physiologic state falls short of the demand. The facilities and financing that would allow maintenance of patients in need of organ transplants, particularly kidneys, are still inadequate and poorly coordinated. But the central obstacle is the rejection reaction, which remains an incompletely solved problem. Nevertheless, it is clear that organ transplants can attain productive life for patients previously near death. An operational solution to the problems of . . .
Radiation Dose-Reduction Program for Cardiac Computed Tomography Angiography—Reply
Authors: Gilbert L. Raff
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Long-term outcome of episodes of major depression. Clinical and public health significance
Authors: M. B. Keller
Journal: JAMA (1984)

Twenty-one percent (20/97) of patients with an episode of major depressive disorder and no history of chronic minor depression who sought treatment at five university medical centers had not recovered after two years of prospective follow-up. The rate of recovery was highest in the three months after entry into the study, with a notable decrease in rate after one year. Most patients who did not recover had severe depressive symptoms throughout the two years of follow-up. Long duration of episode before entry into the study, inpatient hospitalization status at entry, intact marriage, low family income, admitting research center, and a history of nonaffective psychiatric disorders (including alcoholism) predicted a chronic course. The implications of these findings for clinicians, researchers, and public health planners are discussed. (<i>JAMA</i>1984;252:788-792)
Radioisotope techniques in clinical cardiology
Authors: S. M. Spies
Journal: JAMA (1978)

NOTEWORTHY recent advances in both nuclear imaging instrumentation and radiopharmaceutical sciences have been largely responsible for the current revolution in nuclear cardiovascular procedures. The majority of these newer techniques do not require exotic equipment or investigational compounds and can be performed efficiently and accurately in most community hospitals with nuclear medicine facilities. This report describes the current state of the art in nuclear cardiology, with special emphasis given to those techniques that at least preliminarily have shown themselves to be useful in the day-to-day care of cardiac patients. A brief discussion of some exciting new techniques that are currently under investigation will follow. It is thus hoped that the reader will have a feeling for both the current status and the direction of cardiovascular nuclear medicine. <h3>Detection of Acute Myocardial Infarction</h3> The great prevalence of coronary artery atherosclerosis in our society and the rapid advances being made in the area
VITAMIN BALANCE
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Table of contents
Authors: Jeffrey Bernhard, Thomas Cropley, Karen Wiss, Andrew Blauvelt, Oregon Ponciano, D Cruz, Jane Grant-Kels, Nathaniel Jellinek, Rhode Island, Timothy Johnson, Ann Arbor, Alexandra Kimball, Marta Petersen, Salt City, Martin Weinstock, Michael Bigby, Jean Bolognia, New Haven, Luis Diaz, Chapel Hill, Carolina Lebwohl, New York, Donald Miech, Wisconsin Ginat, W Mirowski, Scott Norton, Maryland Olsen, Carolina Orringer, Amy Paller, J Smith, Richard Dobson
Journal: Journal of the American Academy of Dermatology (2006)